InMed Pfcf Ratio vs Invested Capital Analysis

INM Stock

USD 5.26 0.11 2.14%

InMed Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating InMed Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether InMed Pharmaceuticals is a good investment. Please check the relationship between InMed Pharmaceuticals Pfcf Ratio and its Invested Capital accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.

Pfcf Ratio vs Invested Capital

Pfcf Ratio vs Invested Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of InMed Pharmaceuticals Pfcf Ratio account and Invested Capital. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between InMed Pharmaceuticals' Pfcf Ratio and Invested Capital is -0.34. Overlapping area represents the amount of variation of Pfcf Ratio that can explain the historical movement of Invested Capital in the same time period over historical financial statements of InMed Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of InMed Pharmaceuticals' Pfcf Ratio and Invested Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Pfcf Ratio of InMed Pharmaceuticals are associated (or correlated) with its Invested Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Invested Capital has no effect on the direction of Pfcf Ratio i.e., InMed Pharmaceuticals' Pfcf Ratio and Invested Capital go up and down completely randomly.

Correlation Coefficient

-0.34

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Pfcf Ratio

Invested Capital

Invested capital represents the total cash investment that shareholders and debt holders have contributed to InMed Pharmaceuticals. There are two different methods for calculating InMed Pharmaceuticals invested capital: operating approach and financing approach. Understanding InMed Pharmaceuticals invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.

Most indicators from InMed Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into InMed Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.At this time, InMed Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 15th of December 2024, Tax Provision is likely to grow to 7,407, though Enterprise Value Multiple is likely to grow to (2.02).

	2021	2023	2024 (projected)
Interest Expense	96.1K	86.5K	153.3K
Depreciation And Amortization	511.8K	604.5K	634.7K

Interest Expense Depreciation And Amortization

InMed Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Short Long Term Debt Total	Other Current Liab	Current Deferred Revenue	Short Term Debt	Good Will
Total Assets		0.6	0.99	0.2	-0.93	-0.58	0.76	0.92	0.31	-0.11	0.92	0.4	0.34	0.38	0.67	-0.07	-0.26	-0.24	0.6	0.99	0.2	0.36	0.51	-0.33	0.43	0.09
Total Current Liabilities	0.6		0.47	0.35	-0.4	-0.8	0.8	0.45	0.58	-0.1	0.39	0.36	0.3	0.3	0.22	-0.32	-0.27	0.18	0.94	0.52	0.44	0.49	0.88	-0.76	0.76	0.18
Total Stockholder Equity	0.99	0.47		0.13	-0.96	-0.46	0.69	0.95	0.19	-0.1	0.96	0.33	0.26	0.32	0.68	-0.03	-0.25	-0.32	0.46	0.99	0.11	0.26	0.39	-0.24	0.33	0.08
Property Plant And Equipment Net	0.2	0.35	0.13		0.08	-0.32	0.28	-0.09	0.75	0.77	-0.05	0.69	0.49	0.45	0.27	0.07	-0.09	0.39	0.45	0.09	-0.09	0.32	0.17	-0.12	0.4	-0.73
Net Debt	-0.93	-0.4	-0.96	0.08		0.37	-0.63	-0.99	0.01	0.25	-0.98	-0.14	-0.13	-0.18	-0.56	0.13	0.21	0.43	-0.36	-0.97	-0.07	-0.14	-0.35	0.23	-0.19	-0.23
Retained Earnings	-0.58	-0.8	-0.46	-0.32	0.37		-0.52	-0.37	-0.75	0.32	-0.29	-0.72	-0.75	-0.76	-0.21	0.17	0.39	-0.41	-0.9	-0.49	-0.74	-0.81	-0.67	0.55	-0.8	-0.28
Accounts Payable	0.76	0.8	0.69	0.28	-0.63	-0.52		0.64	0.27	0.01	0.67	0.22	0.15	0.09	0.66	-0.18	-0.02	-0.33	0.75	0.74	0.04	0.29	0.86	-0.4	0.38	0.01
Cash	0.92	0.45	0.95	-0.09	-0.99	-0.37	0.64		-0.01	-0.25	0.98	0.11	0.09	0.15	0.53	-0.14	-0.22	-0.43	0.37	0.96	0.07	0.12	0.38	-0.27	0.23	0.28
Non Current Assets Total	0.31	0.58	0.19	0.75	0.01	-0.75	0.27	-0.01		0.23	-0.05	0.83	0.74	0.73	0.12	0.12	-0.31	0.67	0.73	0.17	0.59	0.76	0.33	-0.39	0.82	-0.24
Non Currrent Assets Other	-0.11	-0.1	-0.1	0.77	0.25	0.32	0.01	-0.25	0.23		-0.15	0.17	-0.09	-0.08	0.13	0.08	0.05	0.11	-0.12	-0.16	-0.6	-0.31	-0.2	0.1	-0.1	-0.91
Cash And Short Term Investments	0.92	0.39	0.96	-0.05	-0.98	-0.29	0.67	0.98	-0.05	-0.15		0.1	0.05	0.11	0.64	-0.1	-0.17	-0.5	0.32	0.97	-0.04	0.05	0.38	-0.19	0.16	0.18
Net Receivables	0.4	0.36	0.33	0.69	-0.14	-0.72	0.22	0.11	0.83	0.17	0.1		0.92	0.94	0.34	0.21	-0.35	0.47	0.56	0.29	0.42	0.73	0.22	-0.07	0.6	-0.22
Common Stock Shares Outstanding	0.34	0.3	0.26	0.49	-0.13	-0.75	0.15	0.09	0.74	-0.09	0.05	0.92		0.9	0.32	0.11	-0.12	0.45	0.56	0.24	0.53	0.86	0.19	0.04	0.49	-0.01
Short Term Investments	0.38	0.3	0.32	0.45	-0.18	-0.76	0.09	0.15	0.73	-0.08	0.11	0.94	0.9		0.17	0.16	-0.54	0.49	0.49	0.28	0.57	0.68	0.19	-0.14	0.61	0.01
Non Current Liabilities Total	0.67	0.22	0.68	0.27	-0.56	-0.21	0.66	0.53	0.12	0.13	0.64	0.34	0.32	0.17		0.13	0.28	-0.39	0.3	0.67	-0.16	0.3	0.34	0.24	0.02	-0.16
Inventory	-0.07	-0.32	-0.03	0.07	0.13	0.17	-0.18	-0.14	0.12	0.08	-0.1	0.21	0.11	0.16	0.13		-0.07	-0.14	-0.26	-0.09	0.1	0.16	-0.29	0.53	0.13	-0.08
Other Current Assets	-0.26	-0.27	-0.25	-0.09	0.21	0.39	-0.02	-0.22	-0.31	0.05	-0.17	-0.35	-0.12	-0.54	0.28	-0.07		-0.27	-0.17	-0.22	-0.35	0.03	-0.18	0.53	-0.54	-0.08
Other Stockholder Equity	-0.24	0.18	-0.32	0.39	0.43	-0.41	-0.33	-0.43	0.67	0.11	-0.5	0.47	0.45	0.49	-0.39	-0.14	-0.27		0.28	-0.34	0.55	0.45	-0.1	-0.4	0.53	-0.11
Total Liab	0.6	0.94	0.46	0.45	-0.36	-0.9	0.75	0.37	0.73	-0.12	0.32	0.56	0.56	0.49	0.3	-0.26	-0.17	0.28		0.5	0.53	0.71	0.82	-0.62	0.74	0.09
Total Current Assets	0.99	0.52	0.99	0.09	-0.97	-0.49	0.74	0.96	0.17	-0.16	0.97	0.29	0.24	0.28	0.67	-0.09	-0.22	-0.34	0.5		0.14	0.27	0.47	-0.29	0.33	0.14
Intangible Assets	0.2	0.44	0.11	-0.09	-0.07	-0.74	0.04	0.07	0.59	-0.6	-0.04	0.42	0.53	0.57	-0.16	0.1	-0.35	0.55	0.53	0.14		0.76	0.28	-0.43	0.74	0.53
Short Long Term Debt Total	0.36	0.49	0.26	0.32	-0.14	-0.81	0.29	0.12	0.76	-0.31	0.05	0.73	0.86	0.68	0.3	0.16	0.03	0.45	0.71	0.27	0.76		0.35	-0.12	0.65	0.22
Other Current Liab	0.51	0.88	0.39	0.17	-0.35	-0.67	0.86	0.38	0.33	-0.2	0.38	0.22	0.19	0.19	0.34	-0.29	-0.18	-0.1	0.82	0.47	0.28	0.35		-0.57	0.52	0.24
Current Deferred Revenue	-0.33	-0.76	-0.24	-0.12	0.23	0.55	-0.4	-0.27	-0.39	0.1	-0.19	-0.07	0.04	-0.14	0.24	0.53	0.53	-0.4	-0.62	-0.29	-0.43	-0.12	-0.57		-0.64	-0.15
Short Term Debt	0.43	0.76	0.33	0.4	-0.19	-0.8	0.38	0.23	0.82	-0.1	0.16	0.6	0.49	0.61	0.02	0.13	-0.54	0.53	0.74	0.33	0.74	0.65	0.52	-0.64		0.2
Good Will	0.09	0.18	0.08	-0.73	-0.23	-0.28	0.01	0.28	-0.24	-0.91	0.18	-0.22	-0.01	0.01	-0.16	-0.08	-0.08	-0.11	0.09	0.14	0.53	0.22	0.24	-0.15	0.2

Click cells to compare fundamentals

InMed Pharmaceuticals Account Relationship Matchups

InMed Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	7.5M	9.8M	12.8M	14.1M	11.8M	12.4M
Total Current Liabilities	1.7M	2.2M	3.3M	2.0M	2.0M	1.1M
Total Stockholder Equity	5.6M	7.4M	9.1M	12.1M	9.2M	9.7M
Property Plant And Equipment Net	402.6K	326.6K	904.3K	723.4K	1.2M	1.3M
Net Debt	(5.5M)	(7.1M)	(5.4M)	(8.5M)	(5.6M)	(5.3M)
Retained Earnings	(56.0M)	(74.9M)	(93.5M)	(101.4M)	(109.1M)	(103.6M)
Accounts Payable	959.2K	775.1K	1.2M	544.2K	626.2K	615.9K
Cash	5.8M	7.4M	6.2M	8.9M	6.6M	3.4M
Non Current Assets Total	1.2M	1.4M	3.2M	2.8M	3.1M	3.3M
Cash And Short Term Investments	5.8M	7.4M	6.2M	8.9M	6.6M	3.9M
Net Receivables	45.2K	11.9K	88.0K	260.4K	352.8K	370.5K
Common Stock Shares Outstanding	208.8K	270K	560.8K	2.4M	7.6M	8.0M
Short Term Investments	42.3K	46.5K	44.8K	44.4M	43.1M	45.2M
Liabilities And Stockholders Equity	7.5M	9.8M	12.8M	14.1M	11.8M	12.4M
Non Current Liabilities Total	247.5K	189.3K	389.5K	16.0K	644.9K	677.1K
Inventory	(919.56)	(955.8M)	2.5M	1.6M	1.2M	1.3M
Other Current Assets	418.9K	956.8K	842.0K	(8.9B)	477.7K	501.6K
Other Stockholder Equity	(59.5M)	21.5M	31.7M	35.7M	35.4M	37.1M
Total Liab	1.9M	2.4M	3.7M	2.0M	2.6M	2.7M
Total Current Assets	6.3M	8.4M	9.6M	11.3M	8.7M	9.1M
Accumulated Other Comprehensive Income	59.6M	63.4M	70.8M	128.6K	147.9K	140.5K
Intangible Assets	799.3K	1.1M	2.1M	1.9M	1.8M	1.9M
Common Stock	50.2M	60.6M	70.7M	77.6M	82.8M	53.5M
Net Tangible Assets	6.5M	6.3M	7.0M	10.1M	9.1M	9.1M
Net Invested Capital	5.6M	7.4M	9.1M	12.1M	9.2M	8.4M
Net Working Capital	4.6M	6.2M	6.3M	9.3M	6.7M	7.1M
Property Plant Equipment	549.9K	326.6K	904.3K	723.4K	831.9K	873.5K
Capital Stock	50.2M	60.6M	70.7M	77.6M	82.8M	72.3M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether InMed Pharmaceuticals is a strong investment it is important to analyze InMed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact InMed Pharmaceuticals' future performance. For an informed investment choice regarding InMed Stock, refer to the following important reports:

How To Invest In InMed

Details

Is InMed Stock a good investment?

Details

What is InMed Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.

You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

230.4

Revenue Per Share

0.603

Quarterly Revenue Growth

(0.45)

Return On Assets

(0.39)

Return On Equity

(0.72)

The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

InMed Pfcf Ratio vs Invested Capital Analysis

Pfcf Ratio vs Invested Capital

Pfcf Ratio vs Invested Capital Correlation Analysis

Correlation Coefficient

Pfcf Ratio

Invested Capital

InMed Pharmaceuticals fundamental ratios Correlations

InMed Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

InMed Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Stockholder Equity
Cash And Short Term Investments	+ 0.98	Cash
Total Current Assets	+ 0.97	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.96	Total Stockholder Equity

Cash	- 0.99	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Total Current Assets	- 0.97	Net Debt
Net Debt	- 0.96	Total Stockholder Equity
Net Debt	- 0.93	Total Assets
Good Will	- 0.91	Non Currrent Assets Other